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Available online 22 August 2011Abstract The purpose of this study is to establish a murine embryonic stem cell (mESC) line for isolation of functional
ventricular cardiomyocytes (VCMs) and then to characterize the derived VCMs. By crossing the myosin light chain 2v
(Mlc2v)-Cre mouse line with the reporter strain Rosa26-yellow fluorescent protein (YFP), we generated mESC lines from
these double transgenic mice, in which Cre-mediated removal of a stop sequence results in the expression of YFP under
the control of the ubiquitously active Rosa26 promoter specifically in the VCM. After induction of differentiation via em-
bryoid body (EB) formation, contracting YFP+ cells were detected within EBs and isolated by fluorescence-activated cell
sorting. N-cadherin, the cadherin expressed in cardiomyocytes, and the major cardiac connexin (Cx) isoform, Cx43, were
detected in the respective adherens and gap junctions in these VCMs. Using current clamp recordings we demonstrated
that mESC-derived VCMs exhibited action potential characteristics comparable to those of neonatal mouse VCMs. Real-Abbreviations: AP, action potential; APA, action potential amplitude; APD, action potential duration; CMV, cytomegalovirus; MDP, max-
imum diastolic potential; cTnT, cardiac troponin T; EB, embryoid body; ECC, embryonic carcinoma cell; ESC, embryonic stem cell; GFP,
green fluorescent protein; MEF, mouse embryonic fibroblast; MHC, myosin heavy chain; MI, myocardial infarction; MLC2v, myosin light
chain 2v; VCM, ventricular cardiomyocyte; YFP, yellow fluorescent protein.
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50 M.Y. Lee et al.time intracellular calcium [Ca2+]i imaging showed rhythmic intracellular calcium transients in these VCMs. The amplitude
and frequency of calcium transients were increased by isoproterenol stimulation, suggesting the existence of functional
β-adrenergic signaling. Moreover, [Ca2+]i oscillations responded to increasing frequencies of external electrical stimula-
tion, indicating that VCMs have functional excitation–contraction coupling, a key factor for the ultimate cardiac contrac-
tile performance. The present study makes possible the production of homogeneous and functional VCMs for basic
research as well as for cardiac repair and regeneration.
© 2011 Elsevier B.V. All rights reserved.Introduction
Despite recent advances in pharmacological and surgical ther-
apies, heart disease is the leading cause of mortality and mor-
bidity worldwide (Jessup and Brozena, 2003). Cardiac-related
deaths due to ischemic heart disease are caused by occlusion
of a coronary artery resulting in ventricular myocardial
infarction (MI), which induces extensive myocardial cell
death within the ischemic zone (Freude et al., 2000;
Scarabelli et al., 2001), leading to heart failure (Gepstein,
2010). Cell-based therapies are considered one of the most
promising solutions to regenerate the damaged heart tissue.
In the last decade, several groups reported that transplanta-
tion of isolated fetal or neonatal cardiomyocytes can aid in
the regeneration of damaged heart tissue (Müller-Ehmsen et
al., 2002; Roell et al., 2002). However, these studies were
limited by the availability of fetal and neonatal cardiomyo-
cytes (Reinecke et al., 2008). Current research seeks to ad-
dress these issues by actively pursuing new strategies to
derive novel/additional cell types useful for regenerative
medicine from stem cells.
Embryonic stem cells (ESCs) are derived from the inner cell
mass of the blastocyst stage embryos (Evans and Kaufman,
1981), and they have the ability to produce cells of all three
germ layers, including heart cells (Wobus et al., 1997). Thus,
they can provide an abundant, renewable source of cells for
cardiac repair. Efforts have been made to develop strategies
for cardiac lineage selection and cardiomyocyte differentiation
using ESCs. Heterogenous cultures containing cardiac cells can
be isolated from ESCs in culture (Kehat et al., 2001; Laflamme
et al., 2007; Maltsev et al., 1994; Mummery et al., 2003; Xu et
al., 2002). Commonly, during cardiac differentiation in ESCs,
all cardiac phenotypes including nodal, atrial and ventricular
cells can be detected in ESC cultures (Laflamme et al., 2007;
Yang et al., 2008). However, this phenotypic heterogeneity of
differentiated ESC samples might lead to an inefficient en-
graftment and might cause abnormal electrical activity after
implantation (Zhu et al., 2010; Hansson et al., 2009). Thus, it
is critically important to isolate highly purified cardiac cells.
Ventricular cardiomyocytes (VCMs) are themost extensively
injured cardiac cell type in ischemic heart disease and, as a re-
sult, the leading cause of reduced cardiac function. Therefore,
it is of great interest to generate a renewable source of VCMs
from ESCs for cell-based therapies to treat heart failure. Myo-
sin light chain 2, ventricular isoform (Mlc2v) is specifically
expressed in the ventricular chamber and is required for ven-
tricular chambermorphogenesis during mammalian cardiogen-
esis (Chen et al., 1998; Minamisawa et al., 1999), providing an
ideal marker for the isolation of VCMs. By using an artificial re-
porter system in which enhanced green fluorescent protein(eGfp) is driven by a hybrid promoter composed of a fragment
of Mlc2v promoter and the enhancer element of the cytomeg-
alovirus (CMV), two groups have previously established trans-
genic murine ESC (mESC) and embryonic carcinoma cell
(ECC) lines for the isolation of VCMs, respectively (Moore et
al., 2004; Müller et al., 2000). In the present study, we
established a stable reporter system using endogenous promot-
er specifically activated in VCMs.
TheMlc2v-Cremouse line, in which Cre is knocked into one
of the endogenous Mlc2v loci, is a well-established strain for
marking VCMs (Chen et al., 1998; Minamisawa et al., 1999).
By breeding this Cre line with the conditional Cre reporter
strain Rosa26-yellow fluorescent protein (Yfp) (Abou-Khalil
et al., 2009), we generated ESC lines from the blastocysts of
the double transgenic embryos (Mlc2v-Cre; Rosa26-Yfp) and
isolated VCMs from these ESC lines by using in vitro differenti-
ation. In this study, Cre-mediated removal of a stop sequence
resulted in the expression of YFP under the control of endoge-
nous Rosa26 promoter specifically in VCMs. We further showed
that these ESC-derived VCMs displayed the capacity to form
the functional syncytium, neonatal ventricular cardiomyo-
cyte-like action potentials, and rhythmic intracellular calcium
transients that are responsive to both chemical and electrical
stimulation. This mESC line will allow the production of homo-
geneous, functional VCMs for cell-based ventricular repair and
regeneration in murine heart injury models. This study will set
the stage for the isolation of human VCMs using MLC2V as
marker in human ESCs and induced pluripotent stem cells
(iPSCs) for use in cardiac repair.Results
Establishment of Mlc2v-Cre; rosa26-Yfp mESC line
We generated a mESC line using conditional genetic lineage
tracing. Mlc2v-Cre mice were crossed into the conditional
Cre reporter Rosa26-YFP strain. We isolated the Mlc2v-Cre;
Rosa26-YfpmESC line from day 3.5 embryos (Fig. 1A) and con-
firmed the presence of the Mlc2v-Cre and the Yfp genes in
this mESC line by genomic DNA PCR analysis. Conversely,
wild-type mice express neither Mlc2v-Cre nor the Yfp genes
(Fig. 1B). Additionally, this Mlc2v-Cre; Rosa26-Yfp mESC line
has a normal karyotype (Fig. 1C). To induce cardiac differen-
tiation, embryoid bodies (EBs) derived from mESCs were cul-
tured as previously described (Qyang et al., 2007). After
6 days following EB formation, scattered YFP expression was
detectable in EBs. In order to examine whether YFP expres-
sion correlates with the presence of MLC2v proteins, mESC-
derived beating cluster at day 10 was immunostained with
Figure 1 Derivation of mESC line for isolation of VCMs. (A) A schematic diagram of derivation of theMlc2v-Cre; Rosa26-Yfp double
transgenic mESC line and the isolation of VCMs. Mice carry one Mlc2v-Cre allele and one Rosa26-Yfp reporter gene. (B) PCR-based
genotyping of the Mlc2v-Cre and Yfp genes in the Mlc2v-Cre; Rosa26-Yfp double transgenic mESC line and wild type control (WT).
(C) G-banding chromosome analysis of the Mlc2V-Cre; Rosa26-Yfp mESC line. (D) Immunocytochemical characterization of mESC-
derived ventricular cardiomyocytes. Day 10 EBs were dissociated and replated on the culture plate. YFP fluorescent cells express
MLC2v protein in beating clusters. Inset represents magnified views of the white boxes which show striation pattern of MLC2v.
Scale bar, 100 μm.
51Derivation and functional characterization of VCMs from ESCsanti-MLC2v antibody. This immunohistochemical data demon-
strated the co-expression of YFP and MLC2v protein, which
suggests the expression of VCM markers in YFP+ cells and
YFP could be useful for the purification of VCMs (Fig. 1D).Characterization of FACS-sorted YFP+ VCMs
To characterize the cells expressing YFP in Mlc2v-Cre; Rosa26-
Yfp cultures, EBs were enzymatically-dissociated into single
cells at EB day 10 of cardiac differentiation for FACS analysis.
Examination of the Mlc2v-Cre; Rosa26-Yfp mESC-derived EBs
revealed a distinct population of YFP+ cells that were present
in the Mlc2v-Cre; Rosa26-Yfp mESC-derived EBs, whereas no
distinct YFP+ population was observed in EBs derived from
wild type mESCs (Fig. 2A). To examine whether YFP+ cells
were enriched for VCMmarker Mlc2v, we analyzed FACS-sortedYFP+ cells with q-RT-PCR. BothMlc2v and YfpmRNA were high-
ly enriched in YFP+ cells when compared to those in the YFP−
cell population (Fig. 2B). Additionally, immunocytochemical
analysis revealed that FACS-sorted YFP+ cells were positive
for the cardiomyocyte marker cardiac troponin T (cTnT).
Taken together, our findings suggest that YFP+ cells have the
characteristics of VCMs.Formation of adherens and gap junctions in
FACS-sorted YFP+ VCMs
We next examined the expression of cardiac junctional
proteins in FACS-purified YFP+ VCMs. Immunofluorescence
analysis showed that N-cadherin, a major isoform of cadherins
in the adherens junction, and connexin 43, an important con-
nexin isoform in the gap junctions of cardiomyocytes (Noorman
Figure 2 Isolation of Mlc2v-Cre; Rosa26-Yfp mESC-derived
VCMs. (A) Flow cytometry profile of EB day 10 differentiated
Mlc2v-Cre; Rosa26-Yfp mESCs. Wild type mESCs were used as a
negative control. (B) Quantitative PCR (qPCR) analysis showing
Mlc2v and Yfp gene expression in YFP− cells compared to YFP+
cells isolated from day 10 Mlc2v-Cre; Rosa26-Yfp EBs. The values
are reported as the mean±S.E.M. (n=3). *Pb0.05 vs. YFP−. (C)
Immunostaining of FACS-sorted YFP+ cell from day 10 Mlc2v-Cre;
Rosa26-Yfp EBs shows cTnT expression. Inset represents magnified
views of the white boxes which show striation pattern of cTnT.
Scale bar, 20 μm.
52 M.Y. Lee et al.et al., 2009), were clearly expressed at cell–cell interfaces
(Figs. 3A and B). These results suggest that YFP+ VCMs can
form cardiac junctions. Importantly, N-cadherin and connexin
43 were also co-expressed with MLC2v in neonatal VCMs. Addi-
tionally, the protein expression levels and localization patterns
for N-cadherin and connexin 43 were similar between neonatal
VCMs and YFP+ VCMs (Figs. 3C and D). Our findings suggest that
YFP+ VCMs express characteristic VCM junctional proteins and
possess the ability to form cardiac junctions.Action potential recordings of YFP+ VCMs
In order to examine the functionality of FACS-sorted YFP+
VCMs, cells were replated on gelatin-coated 25 mm glass cov-
erslips (Fig. 4A), andweanalyzed their action potential charac-
teristics. Whole-cell current clamp electrophysiology analysisshowed that FACS-purified YFP+ cells showed ventricular-like
action potentials whereas atrial- or nodal-like action potentials
were not observed (Fig. 4B). The action potentials of YFP+ cells
were comparable to those of neonatal mouse ventricular cardi-
omyocytes with respect to maximum diastolic potential (MDP)
and upstroke velocity (dV/dtmax). Interestingly, we also ob-
served that YFP+ VCMs showed a modest decrease in action po-
tential amplitude (APA) and a significant prolongation of action
potential duration at 90% repolarization (APD90) as compared
to neonatal mouse VCMs. These results suggest that our ES
cell-derived VCMs exhibit action potentials characterized by
premature ventricular patterns.
[Ca2+]i transient imaging of YFP
+ VCMs
To determine the contractile properties of YFP+ VCMs, we per-
formed real-time intracellular calcium [Ca2+]i imaging analysis.
After loading VCMs with the Ca2+ indicator dye, fluo-4 AM, we
assessed changes in intracellular Ca2+ at a single-cell level in
YFP+ cells by measuring minimum (Ca2+min) and maximum
(Ca2+max) [Ca2+]i using fluorescent microscopy (Fig. 5A). Addi-
tionally, we observed periodic Ca2+ oscillations in YFP+ cells
and found that both calcium transient amplitude and frequency
were increased by isoproterenol treatment (Fig. 5B). Addition-
ally, [Ca2+]i oscillations responded to increasing frequencies of
external electrical field stimulation (Fig. 5C). These data sug-
gest that the β-adrenergic signaling pathway and cardiac exci-
tation–contraction coupling, a key factor for the ultimate
cardiac contractile performance, are present in YFP+ cells.
Discussion
MLC2v is expressed exclusively in the ventricles (Chen et al.,
1998; Minamisawa et al., 1999), where it contributes to the for-
mation of sarcomeres and increases Ca2+ sensitivity at submax-
imal Ca2+ concentrations (Chen et al., 1998; Olsson et al.,
2004). The present study demonstrates that Mlc2v-Cre;
Rosa26-Yfp mESCs can differentiate into cardiac lineages and
that VCMs can be isolated based on YFP expression. Several
groups have reported that transplantation of cardiomyocytes
derived from ESCs improves cardiac function after myocardial
injury in rodent animal models (Laflamme et al., 2007; Klug
et al., 1996; van Laake et al., 2007). However, successful ther-
apy with ESC-derived donor cells is likely to require the gener-
ation of a highly purified cardiomyocyte population (Klug et
al., 1996; Zandstra et al., 2003). Application of mixed cell
populations into an injured left ventricle might trigger proar-
rhythmic effects due to the presence of inappropriate cell
types such as nodal- and atrial-like cells (Zhang et al., 2009).
In addition, a preparation containing undifferentiated cells
could lead to tumorigenesis/teratoma formation. Thus, the
production of homogenous and functional cardiomyocytes is a
prerequisite for cell-based therapies. To date, cardiomyocyte
markers like alpha myosin heavy chain (α-MHC) (Kita-Matsuo
et al., 2009) and α-actinin (Kolossov et al., 1998) have been
used to isolate cardiomyocytes from ESCs. However, the cardi-
ac differentiation of ESCs leads to a heterogeneous population
of nodal-, atrial-, and ventricular-like derivatives (He et al.,
2003; Moore et al., 2008), and these markers lack the specific-
ity needed for distinguishing between different types of cardi-
omyocytes. A significant percentage of cardiac-related deaths
Figure 3 N-cadherin and connexin 43 protein expression in YFP+ VCMs and neonatal VCMs. Immunocytochemistry showed that N-cadherin
and connexin 43 are expressed in FACS-sorted YFP+ VCMs (A and B) and MLC2v expressing neonatal VCMs (C and D). Insets represent
magnified views of the white boxes and show that N-cadherin (white arrow heads) and connexin 43 (red arrow heads) are expressed at
cell–cell interface. Scale bar, 50 μm.
53Derivation and functional characterization of VCMs from ESCsis due to ischemic heart disease related to myocardial infarc-
tion in the ventricles (Thom et al., 2006). Therefore, it is crit-
ical to develop stem cell-based therapies for the regeneration
of injured ventricular tissue.
We derived ESC lines from blastocysts of the double trans-
genic mouse line Mlc2v-Cre; Rosa26-Yfp, in which Cre and
Yfp are specifically knocked into the Mlc2v and Rosa26 gene
loci, respectively. Mlc2v-Cre-mediated removal of a stop se-
quence in the Rosa26-YFP reporter line results in expression
of YFP under the control of the ubiquitous Rosa26 promoter
specifically in the VCM. Importantly, our analysis demonstrated
that these YFP+ cells express both Mlc2v transcript and MLC2v
protein compared to YFP− cells by q-RT-PCR and immunocyto-
chemistry. YFP+ cells were 1.05±0.13% and cTnT+ cells were
5.13±0.01% out of total cells in our system (Supplementary
Fig. 1). This result suggests that approximately 20% of total car-
diomyocytes are VCM (Supplementary Fig. 1). It should be
noted that YFP expression may not fully represent the total
population of VCMs. Cre-mediated recombination and subse-
quent activation of YFP expression in VCMs is typically not
100%, which presents the possibility for the existence of VCMs
that are not YFP+ (Fig. 1D). Furthermore, the ventricular iden-
tity and functionality of YFP+ cells were determined by analyz-
ing electrophysiological characteristics. We observed that the
action potentials (APs) of YFP+ cells showed ventricular
morphology comparable to those of neonatal mouse ventricu-
lar cardiomyocytes, as determined by maximum diastolic
potential (MDP) and upstroke velocity (dV/dtmax). Interesting-
ly, we observed that YFP+ VCMs showed a modest decrease in
action potential amplitude (APA) and a significant prolongationof action potential duration at 90% repolarization (APD90) in
comparison with neonatal mouse VCMs. Comparison of these
electrophysiological values suggests that YFP+ cells isolated
from EB day 10 are not as mature as neonatal ventricular cardi-
omyocytes (Wang and Sobie, 2008). In contrast to previous
studies in which cardiomyocytes purified using promoter DNA
constructs showed ventricular, atrial and nodal AP morpholo-
gy, we observed exclusively ventricular AP morphology in our
purified VCMs. We were also able to monitor Ca2+ transients,
and we observed that our FACS-purified YFP+ cells showed pe-
riodic calcium oscillations that are responsive to both isopro-
terenol and electrical stimulation. Taken together, these
results suggest that our FACS-purified YFP+ cells represent a
differentiated ventricular cardiac phenotype.
Recently, two independent research groups utilized mito-
chondrial dyes and the cellular prion protein as markers to
purify cardiomyocytes from ESCs without genetic manipula-
tion (Hattori et al., 2010; Hidaka et al., 2010). These
represent an important step toward cardiomyocyte isolation
without using genetic engineering methods. However, the
cardiomyocytes isolated by these methods were still a
mixture of atrial, ventricular and nodal cardiomyocytes. By
using microarray analysis to compare the gene expression
profiles of YFP+ VCMs and YFP− cells derived from our cur-
rent study, it may be possible to identify cell surface
markers specific to VCMs and lead to the purification of
VCMs with FACS, thereby avoiding the use of genetic engi-
neering. In addition, VCMs hold the potential to be used as
cell-based therapies for treatment of degenerative heart
diseases.
Figure 4 Actionpotential recording incontractingFACS-sorted
YFP+ VCMs. (A) Representative image of FACS-sorted YFP+ VCMs in
which action potentials are recorded bywhole-cell current clamp
modeusingapatch-clampamplifier. Scalebar,100 μm.(B)Action
potentials in a YFP+ VCMs and a neonatal VCMs. (C) Summarized
data showing dV/dt (themaximum rate of rise of action potential
stroke),APA(actionpotentialamplitude),APD90(actionpotential
durationat90%ofrepolarization)andMDP(themaximumdiastolic
potential). Neonatal VCMs (n=20) and YFP+ VCMs (n=40) from 3
different batches were analyzed. The values are reported as the
mean±S.E.M.
Figure 5 Real time [Ca2+]i transients in contracting FACS-sorted
YFP+ VCMs. (A) Representative fluorescence and pseudo-colored
images of spontaneous contracting YFP+ VCMs showing minimal
(Ca2+min) and maximal (Ca
2+
max) fluo-4 fluorescence intensity. Cir-
cles indicate the area used to measure Ca2+. (B) Increase in [Ca2+]i
transient amplitude and frequency in YFP+ VCMs under isoprotere-
nol stimulation (500 nM). (C) Calcium transients of YFP+ VCMs in
response to electrical pacing at various frequencies.
54 M.Y. Lee et al.Despite the advances presented in this work, several
challenges remain. Due to potential variations in the degree
of cardiomyocyte differentiation between batches of dif-
ferentiated ES cells, there may be non-uniformity when
measuring action potentials and calcium transients of YFP+
VCMs. Therefore, techniques are needed to develop pheno-
typically mature cardiomyocytes, as opposed to the imma-
ture ventricular phenotype observed in this study.
Physiological stimuli such as mechanical stretch, shear
stress and electrical pacing may help to promote cardio-
myocyte maturation. Another challenge to be surmounted
will be the development of a non-transgenic based ap-
proach to VCM isolation in order to maximize clinical appli-
cation. Translation of the reported transgenic VCMs into
clinical utility requires a non-transgenic approach to the
isolation of VCMs. Future efforts are warranted to identify
cell surface markers specific to VCMs using our purified
transgenic VCMs. Third, in vivo electrical integration of
VCMs with host cardiomyocytes needs to be investigated in
the future in order to evaluate the potential of VCMs for car-
diac repair.Conclusion
This is the first study to derive functional VCMs using the
Mlc2v endogenous promoter at a precise chromosal locus.
Our mESC line will allow the production of homogeneous
and functional VCMs for basic research as well as for cell-
based ventricular repair and regeneration. This strategy of
using the human MLC2v endogenous promoter to direct the
expression of a reporter construct can also be applied to
human ES cells and induced pluripotent stem (iPS) cells for
VCM isolation and cardiac research and cardiac repair.
Materials and methods
Generation of Mlc2v-Cre; Rosa26-Yfp mouse embry-
onic stem cells (ESCs)
The Mlc2v-Cremouse line, in which Crewas knocked into the
endogenous Mlc2v locus, was crossed into the conditional
Cre reporter strain Rosa26-Yfp, in which Cre-mediated
55Derivation and functional characterization of VCMs from ESCsremoval of a stop sequence results in the ubiquitous expres-
sion of YFP under the control of an endogenous Rosa26 pro-
moter specifically in the ventricular cardiomyocytes. ESC
lines were derived from these double transgenic mice as pre-
viously described (Qyang et al., 2007). Briefly, timed mat-
ings were performed and on embryonic day 3.5, the
females were sacrificed and the blastocysts flushed from
the uterine horns using M2 medium (Sigma-Aldrich, MO).
After washing with M2 medium, the zona pellucid was re-
moved with acidic Tyrode's Solution (Sigma-Aldrich, MO).
After washing, the blastocyts were then adapted onto
mouse embryonic feeder (MEF) cells for 7–10 days.
ESC culture and differentiation
Mouse ESCs were cultured for 3 days in Dulbecco's modified
Eagle's medium (Invitrogen) supplemented with 1% penicillin
and streptomycin (Invitrogen), 2 mM L-glutamine, 0.1 mM
non-essential amino acid (MEM-NEAA; Invitrogen), 1 mM so-
dium pyruvate (Invitrogen), 0.1 mM 2-mercaptoethanol
(Sigma), LIF-conditioned media (1:500 dilution), and 15%
Knock-out serum replacement (KO-SR; Invitrogen) on a
mouse embryonic fibroblast (MEF) feeder layer. These cells
were dissociated into single cells with 0.25% trypsin-EDTA
(Invitrogen), and transferred to gelatin-coated 60 mm
culture dishes and cultured in Iscove's modified Dulbecco's
medium supplemented with 2 mM L-glutamine, 1% penicillin
and streptomycin, 0.1 mM 1-thioglycerol (Sigma), LIF-
conditioned medium, and 15% KO-SR for 2 days, to deplete
the feeder cells. For differentiation, 540 ESCs in 15 μl
aliquots of IMDM supplemented with 2 mM L-glutamine,
0.1 mM 1-thioglycerol, and 15% fetal bovine serum (FBS)
were cultured in hanging drops for 2 days. The resultant indi-
vidual embryoid bodies (EBs) were transferred to gelatin-
coated culture dishes. Spontaneous contraction of EBs
started 5.5 days after EB formation.
Fluorescence-activated cell sorting (FACS) and FACS
analysis
At 10 days from EB formation, EBs were dissociated into sin-
gle cell suspensions with a 1:1 solution of collagenase A and
B (Roche) (6.67 mg/ml) for 30 min with periodic pipetting
followed by digestion with Accutase® for 5 min. Cells were
collected by centrifugation (1000 rpm for 5 min), washed
with phosphate-buffered saline (PBS; Invitrogen), and then
resuspended in PBS (1 ml) for FACS analysis. Sorting was per-
formed using a Becton Dickenson FACSAria (BD Biosciences).
YFP+ and YFP− cells were sorted using the FL1 channel at low
sheath pressure. Sorted cells were pelleted by centrifuga-
tion (1000 rpm for 5 min) and then used for subsequent ap-
plications. In addition, samples were also analyzed using
FACSCalibur and Cell Quest software (BD Pharmingen).
Isolation of neonatal cardiomyocytes
Mouse hearts isolated from 1-day-old mouse pups were
washed in ice-cold Hank's balanced salt solution without
Ca2+ (HBSS) and predigested overnight in 0.5 mg/ml tryp-
sin-HBSS solution at 4 °C under constant shaking. Cardiac
cells were obtained after four rounds of 10 min digestionswith 240 units/ml collagenase type II (Worthington) in HBSS
at 37 °C. The cardiomyocyte fraction was separated from
non-cardiomyocytes by two rounds of 1 h differential plating
on gelatin-coated culture dishes in DMEM/M-199 (3:1 ratio)
medium containing 2 mM HBSS, 1% penicillin-streptomycin,
10% horse serum and 5% FBS at 37 °C. Under these condition
non-cardiomyocytes preferentially attach on the culture
dish. Non-adherent cardiomyocytes were collected and cul-
tured until usage.
RNA isolation and quantitative RT-PCR
The total RNA was extracted using TRIzol® reagent and an
RNA extraction kit (Qiagen). Reverse transcription was per-
formed on a Mastercycler® system (Eppendorf) using an
iScript cDNA synthesis Kit (Bio-rad). The real-time quantifi-
cation of RNA targets was performed on a CFX96™ real time
system (Bio-Rad) using a Bio-Rad IQ SYBR green supermix
(Bio-Rad). The primers were 5′-tgaccacacaagcagagagg-3′
(sense), 5′-ccgtgggtaatgatgtggac-3′ (antisense) for Mlc2v;
5′-acttcaagatccgccacaac-3′ (sense), 5′-gaactccagcaggac-
catgt-3′ (antisense) for yfp; 5′-ggtgctgagtatgtcgtgga-3′
(sense), 5′-cggagatgatgacccttttg-3′ (antisense) for Gapdh.
The reaction mixture (10 μl) contained 100 ng of total RNA,
0.5 μM of each primer, enzymes, and fluorescent dyes. The
data was collected during the extension step and was
analyzed using the manufacturer's software. The expression
of genes of interest was normalized to that of Gapdh in
qPCR.
Immunocytochemistry
YFP+ and YFP− cells were plated in gelatin-coated culture
plates and cultured for 3 days following FACS-sorting. Cells
were fixed with 4% paraformaldehyde in PBS and permeabi-
lized for 10 min with PBST (PBS containing 0.1% (v/v) Triton
X-100) and washed 3 times with PBS, 10 min each wash.
Cells were pre-incubated with 10% normal goat serum
(NGS; Invitrogen) in PBST for 45 min in order to decrease
non-specific antibody binding. Cells were then incubated
for 60 min with primary antibody in a solution containing
1% (v/v) NGS in PBST and washed three times for 10 min
with PBST. Primary antibodies were as following: anti-
Mlc2v antibody (1:20 dilution) (Alexis Corp., CA), anti-
cTnT (1:500 dilution) (Lab Vision Corp., CA), anti-YFP anti-
body (1:400 dilution) (invitrogen), anti-N-cadherin antibody
(1:200 dilution) (Snata cruz biotechology, CA), and anti-
connexin 43 antibody (1:200 dilution) (Sigma-aldrich, MO).
Cells were incubated with 1% (v/v) NGS for 60 min with
FITC-conjugated anti-mouse or anti-rabbit secondary anti-
body (1:1000 dilution) (invitrogen) in PBST containing 1%
(v/v) NGS, and washed three times with PBS, for 10 min
each wash. Samples were visualized with a confocal micro-
scope (Nikon) and a fluorescence microscope (Nikon) with
a 100× and 600× objectives.
Whole-cell current clamp recording of action
potentials
Action potential waveforms were recorded from single YFP+
cells or primary cultured mouse neonatal cardiomyocytes
56 M.Y. Lee et al.under whole-cell current clamp mode using an EPC9 patch-
clamp amplifier and Pulse+Pulsefit software (HEKA Electro-
nik, Lambrecht/Pfalz, Germany) at room temperature.
Patch pipettes were pulled from borosilicate glass tubes to
give a resistance of 1.5–3.0 MΩ when filled with pipette so-
lution. After formation of giga seal (>1.5 GΩ), whole-cell
configuration was achieved by suction on the pipette in com-
bination with Zap. The fast and slow capacity transients
were canceled using computer-controlled circuitry of the
patch-clamp amplifier before switching to current clamp
mode. Spontaneous action potential firings of the cells
were recorded under continuous recording mode. Data
were low-pass filtered at 2 kHz and digitized at a rate of
10 kHz. The bath solution contained 140 mM NaCl, 3 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH7.3 and the
pipette solution was 145 mM KCl, 5 mM NaCl, 2 mM CaCl2,
2 mM MgCl2, 3 mM MgATP, 4 mM EGTA, and 10 mM HEPES,
pH7.3.Calcium transient measurement
YFP+ cells were plated on gelatin-coated cover slips and cul-
tured for 7 days. Cells were loaded with 25 μM cell permeant
calcium indicator dye fluo-4 AM (Invitrogen) together with
0.1% Pluronic F-127 (Invitrogen) in Tyrode's solution contain-
ing 2.5 mM calcium at 37 °C for 30 min. Before imaging, the
cells were allowed to de-esterify for 30 min in Tyrode's
solution at 37 °C. The coverslips were placed into a stimula-
tion chamber (RC-21BRFS; Warner Instruments) containing
Tyrode's solution and mounted onto an inverted fluorescence
microscope (Nikon Diaphot-TDM). 30 μM blebbistatin (Sigma)
was used in the chamber to arrest contraction of the
cardiomyocytes. Measurements were repeated without
blebbistatin to rule out its potential effect on the calcium
transients. The sample was illuminated with a Nikon H-9
100 W lamp powered by a short arc DC power supply (Chiu
Technical Corporation) and the light was filtered with a
Chroma 41001 filter set (HQ535/50 m emission, HQ480/40x
excitation, BS Q505LP dichroic; Chroma Technology
Corporation). Data acquisition was performed at room
temperature. Data was captured with a NeuroCCD camera
(RedShirtImaging), acquired at 125 frames per second, and
analyzed with Neuroplex Software (RedShirtImaging).
Fluorescence was measured by manually defining each re-
gion of interest and quantified in relation to baseline fluo-
rescence (F/F0). The samples were electrically stimulated
by field pacing (10v, 10 ms bipolar pulses at 1–4 Hz). The
samples were chemically stimulated with the β-adrenocep-
tor agonist isoproterenol (Sigma), which was added to the
chamber and mixed for a final concentration of 500 nM.Statistical analysis
The results were reported as the mean±standard error of
the mean (S.E.M.), and experiments were analyzed by Stu-
dent's t-test. Statistical significance was defined as P
valuesb0.05.Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2011.08.004.Disclosures
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